Get the Stockscreener App
7.355
1.10%
0.115
Recursion Pharmaceuticals Inc stock is traded at $7.355, with a volume of 17.90M.
It is up +1.10% in the last 24 hours and down -2.27% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
See More
Previous Close:
$7.24
Open:
$7.35
24h Volume:
17.90M
Relative Volume:
1.17
Market Cap:
$2.83B
Revenue:
$64.60M
Net Income/Loss:
$-377.75M
P/E Ratio:
-4.7452
EPS:
-1.55
Net Cash Flow:
$-335.64M
1W Performance:
+1.10%
1M Performance:
-2.27%
6M Performance:
+14.91%
1Y Performance:
-19.82%
1-Day Range:
$7.27
$7.88
1-Week Range:
$6.89
$8.28
52-Week Range:
$5.60
$15.74
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
7.355 | 2.83B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.86 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.27 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.11 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.38 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.82 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Why Recursion Pharmaceuticals (RXRX) Stock Went Down On Thursday? - Insider Monkey
Recursion Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:RXRX) - MarketBeat
Where Recursion Pharmaceuticals Stands With Analysts - Benzinga
Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Recursion Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RXRX) - MarketBeat
BlackRock, Inc. Expands Stake in Recursion Pharmaceuticals Inc. - GuruFocus.com
Recursion Presents Phase 2 Data for REC-994 in CCM in - GlobeNewswire
Recursion Announces Promising Clinical Data on Lead AI-Based Drug Candidate for Brain Disease - Genetic Engineering & Biotechnology News
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - AOL
Institute for Wealth Management LLC. Makes New Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Inside Recursion’s Pipeline: Najat Khan On AI, Data Science And Biotech Innovation - In Vivo
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 9%Here's Why - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5.6%Should You Sell? - MarketBeat
Why Recursion Pharmaceuticals Stock Is Tumbling Thursday - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 9% HigherHere's Why - MarketBeat
Objective long/short (RXRX) Report - Stock Traders Daily
3 Monster Stocks to Hold for the Next 10 Years - Yahoo Finance
Biotech Stocks To ConsiderJanuary 31st - MarketBeat
How Is The Market Feeling About Recursion Pharmaceuticals? - Benzinga
As Pipeline Advances, Recursion Expands AI Focus to Clinical Trials - Genetic Engineering & Biotechnology News
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo Finance
Institutional owners may consider drastic measures as Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) recent US$130m drop adds to long-term losses - Yahoo Finance
Is Recursion Pharmaceuticals (RXRX) the Cheap AI Stock to Buy in 2025? - MSN
12 Cheap AI Stocks to Buy in 2025 - Insider Monkey
AI Pharma: 2 Paths to AI-Powered Drug Investment - MarketBeat
Recursion Pharmaceuticals (RXRX) Moves 8.9% Higher: Will This Strength Last? - MSN
Nvidia-Backed Recursion Pharma Hits 3-Week High, Sparks Retail Buzz Amid Broader AI Hype - MSN
45,800 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Acquired by Accel Wealth Management - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 6.4% HigherShould You Buy? - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap DownTime to Sell? - MarketBeat
What is Leerink Partnrs’ Forecast for RXRX FY2024 Earnings? - Defense World
Recursion Pharmaceuticals (RXRX): Industrializing Drug Discovery with AI Amid J.P. Morgan’s ‘Neutral’ Outlook - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap UpTime to Buy? - MarketBeat
FY2024 Earnings Estimate for RXRX Issued By Leerink Partnrs - MarketBeat
Why Recursion Pharmaceuticals, Inc. (RXRX) Soared on Wednesday - MSN
Investors Purchase High Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):